We are live on ! Find out more
NKGN

NKGen Biotech, Inc. Common Stock
NKGN

Delisted

NKGN was delisted on the 4th of March, 2025.

Back to rankings

53 hedge funds and large institutions have $143M invested in NKGen Biotech, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

16% more capital invested

Capital invested by funds: $123M → $143M (+$19.2M)

10% more funds holding

Funds holding: 48 → 53 (+5)

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

Holders
53
Holders Change
+5
Holders Change %
+10.42%
% of All Funds
0.91%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
8
Reduced
8
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MF
Magnetar Financial
Illinois
+$8.97M
2
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$8.78M
3
Marshall Wace
Marshall Wace
United Kingdom
+$5.23M
4
MP
Mangrove Partners
Connecticut
+$1.79M
5
GF
Gabelli Funds
New York
+$1.76M

Top Sellers

Rank Fund Capital Flow
1
KC
Kepos Capital
New York
-$5.1M
2
Parallax Volatility Advisers
Parallax Volatility Advisers
California
-$1.59M
3
CL
CSS LLC
Illinois
-$1.29M
4
FBCM
Fort Baker Capital Management
California
-$981K
5
UOC
UBS O'Connor
Illinois
-$318K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIMCA
26
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$1.95M – – –
RCM
27
Rivernorth Capital Management
Florida
$1.94M +$18.7K +1,913 +1%
MP
28
Mangrove Partners
Connecticut
$1.79M +$1.79M +183,800 New
CL
29
CSS LLC
Illinois
$1.55M -$1.29M -131,948 -45%
ACM
30
Atalaya Capital Management
New York
$1.46M – – –
CH
31
CVI Holdings
Delaware
$1.46M – – –
JP Morgan Chase
32
JP Morgan Chase
New York
$980K – – –
OCM
33
Oaktree Capital Management
California
$975K – – –
SC
34
Sculptor Capital
New York
$975K – – –
GCIA
35
Gabelli & Co Investment Advisers
New York
$840K – – –
ETH
36
Exos TFP Holdings
New York
$700K +$701K +71,810 New
IA
37
Icon Advisers
Colorado
$641K +$436K +44,682 +212%
TI
38
Telemetry Investments
New York
$581K – – –
PI
39
PEAK6 Investments
Illinois
$538K – – –
COPPSERS
40
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$488K – – –
Walleye Capital
41
Walleye Capital
New York
$433K – – –
SSA
42
Schonfeld Strategic Advisors
New York
$405K -$111K -11,408 -22%
Walleye Trading
43
Walleye Trading
New York
$351K – – –
AA
44
AQR Arbitrage
Connecticut
$341K +$215K +22,000 +169%
MC
45
Meteora Capital
Florida
$339K +$339K +34,746 New
HighTower Advisors
46
HighTower Advisors
Illinois
$256K -$58.5K -6,000 -19%
VF
47
Virtu Financial
New York
$227K +$227K +23,304 New
FA
48
Fountainhead AM
New Jersey
$145K +$145K +14,911 New
Susquehanna International Group
49
Susquehanna International Group
Pennsylvania
$135K +$135K +13,837 New
CIM
50
Corbyn Investment Management
Maryland
$110K – – –
1
2
3

NKGN Hedge Fund Activity: Q3 2022 in Review

53 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q3 2022, worth a combined $143M — up 16% from $123M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new NKGN positions and 3 closed out — a net gain of 6 holders — while 8 added to existing stakes and 8 trimmed.

The largest buyer was Magnetar Financial, adding an estimated $8.97M. The largest seller was Kepos Capital, exiting entirely with an estimated $5.1M sold.

  • 53 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q3 2022, up from 48 in Q2 2022.
  • Funds reported $143M of NKGen Biotech, Inc. Common Stock stock for Q3 2022, up 16% quarter-over-quarter.
  • 9 funds opened new NKGen Biotech, Inc. Common Stock positions in Q3 2022 and 3 closed out, a net change of +6 holders.
  • The largest NKGen Biotech, Inc. Common Stock buyer in Q3 2022 was Magnetar Financial, an estimated $8.97M added.
  • The largest NKGen Biotech, Inc. Common Stock seller in Q3 2022 was Kepos Capital, an estimated $5.1M sold.

Based on aggregated 13F filings for Q3 2022.